What is the current market size?

The Cisplatin Injection market size was valued at USD 1.2 billion in 2023, driven by its widespread use in oncology treatments globally.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2031, with increasing demand for cancer therapies.

What are the key drivers of growth?

Key drivers include rising cancer prevalence, advancements in drug delivery systems, and growing geriatric populations.

What challenges does the market face?

Challenges include adverse side effects of cisplatin, stringent regulatory requirements, and the availability of generic alternatives.

Which regions are leading the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and high cancer incidence rates.

Who are the top companies in the market?

Leading players include Bristol-Myers Squibb, Accord Healthcare, and Fresenius Kabi, focusing on product innovation and strategic partnerships.

What future opportunities exist?

Emerging markets in Asia-Pacific and Latin America present significant growth opportunities due to improving healthcare access and awareness.

How is technology impacting the market?

Advances in precision oncology and targeted therapies are enhancing cisplatin’s efficacy, driving adoption in combination treatments.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA enforce strict approvals, emphasizing safety and efficacy, while also promoting drug accessibility initiatives.

Cisplatin Injection Growth Opportunities & Strategic Forecast 2033

Cisplatin Injection by Application (NSCLC, Ovarian Cancer, Testicular Cancer, Other), by Types (50ml, 100ml, 200ml), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cisplatin Injection Market Overview

Cisplatin Injection is a platinum-based chemotherapeutic agent, primarily used in the treatment of solid tumors such as testicular, ovarian, bladder, and lung cancers. As a cornerstone in oncology, it remains critical for Cisplatin Injection market size and growth outlook, with the global market estimated at $1.2 billion in 2026, reflecting steady industry expansion driven by rising cancer prevalence and advancements in drug delivery technologies.

Loading chart…

The Cisplatin Injection market forecast projects a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033, fueled by macro drivers such as increasing geriatric populations and rising demand for cost-effective cancer therapies. Key forces reshaping the industry include advancements in nanoparticle drug delivery to mitigate toxicity and regulatory shifts favoring biosimilars, which intensify competitive dynamics. North America dominates the market due to high R&D investment, while Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and rising cancer awareness. Strategic partnerships among players like Bristol-Myers Squibb and Sanofi are pivotal in addressing supply-chain constraints and expanding global access.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Nanjing Pharmaceutical Factory; Lingnan Pharmacy; Hansoh Pharma; Bievalley; Yunnan Phytopharmaceutical; Qilu Pharmaceutical; Luoxin; Jinzhou Jiutai Pharmaceutical; Fresenius Kabi; Teva; Cipla; Hospira(Pfizer); Taj Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Cisplatin Injection market demand is surging due to the rising prevalence of testicular, ovarian, and bladder cancers, which drives oncologists to adopt this platinum-based chemotherapeutic agent as a first-line treatment. The Cisplatin Injection market size is further bolstered by advancements in combination therapies enhancing efficacy in metastatic cancers.

Technological innovations in liposomal encapsulation and targeted drug delivery systems are improving patient compliance and reducing side effects, positioning Cisplatin Injection market growth for a 2024–2032 growth forecast of 6.8% CAGR as per industry data.

Restraints2 items

Regulatory complexities in Cisplatin Injection market expansion persist due to stringent approvals for new formulations, particularly in the EU, where the EMA mandates extensive toxicity trials.

Severe nephrotoxicity and neurotoxicity associated with cisplatin limit its use in elderly patients, reducing market penetration despite its therapeutic efficacy.

Opportunities2 items

Rising R&D investments in personalized cancer therapies offer a strategic growth avenue for Cisplatin Injection market players, enabling tailored dosing protocols to mitigate adverse effects.

Emerging markets in Asia-Pacific present untapped potential as rising disposable incomes and expanding healthcare infrastructure increase access to oncology treatments.

Challenges2 items

Price erosion from biosimilar competition threatens profit margins in the Cisplatin Injection market, particularly in the U.S., where Medicare Part B reimbursement pressures are acute.

Supply chain vulnerabilities—including raw material shortages and geopolitical trade disruptions—pose operational risks for manufacturers, delaying product availability in key regions.

Market Segmentation

Loading chart…

Application segmentation in the Cisplatin Injection market is critical to understanding demand drivers. The primary applications include _Ovarian Cancer_, _Testicular Cancer_, _Lung Cancer_, and _Other oncological indications_ such as bladder and head/neck cancers. Cisplatin Injection segmentation by application reveals that Ovarian and Testicular cancers dominate due to cisplatin’s established role in first-line therapies. Lung Cancer, particularly non-small cell variants, accounts for a growing share as combination protocols expand. The “Other” category, including rare cancers, contributes 15–20% of revenue, reflecting niche but consistent demand. Application-specific R&D and treatment guidelines directly influence market dynamics, with oncology departments and hospital pharmacies driving procurement patterns.

Types segmentation categorizes Cisplatin Injection into _Diamminedichloroplatinum (DDP)_ and _Disodium Salt_ formulations. DDP, the traditional form, retains 60–65% market share due to its broad compatibility with existing delivery systems and cost-effectiveness. Disodium Salt, a newer variant, commands 35–40% growth annually, driven by improved stability and reduced reconstitution complexity. This market taxonomy highlights a shift toward formulations with enhanced therapeutic profiles, particularly in regions prioritizing patient safety and workflow efficiency. Formulation choice impacts procurement decisions, with hospitals in emerging markets favoring DDP for affordability, while advanced healthcare systems adopt Disodium Salt for its logistical benefits.

Cisplatin Injection Segmentation Breakdown9 items

Application

NSCLC

Ovarian Cancer

Testicular Cancer

Other

Types

50ml

100ml

200ml

Regional Insights

Loading chart…

North America dominates the Cisplatin Injection market with a 35% share, driven by advanced oncology infrastructure, high adoption rates for cancer therapies, and robust R&D investments. The region’s Cisplatin Injection market growth is further fueled by aging demographics and rising cancer incidence. Europe follows at 30%, supported by stringent regulatory frameworks, strong public healthcare systems, and growing investments in precision medicine. The Asia Pacific region, with 25% share, is the fastest-growing due to expanding healthcare access, rising awareness of oncology treatments, and a young, large population. Latin America (8%) and the Middle East & Africa (2%) face slower growth but show potential through improving infrastructure and partnerships with global pharma players.

Key Drivers by Region5 items

North America: High adoption of advanced therapies, aging population, and strong ecosystem maturity.

Europe: Favorable reimbursement policies, R&D investments, and mature healthcare infrastructure.

Asia Pacific: Rising cancer incidence, government initiatives for healthcare access, and demographic shifts.

Latin America: Increasing private-sector investments and partnerships to address treatment gaps.

Middle East & Africa: Improved healthcare infrastructure and growing focus on oncology care.

The regional forecast for Cisplatin Injection highlights Asia Pacific’s potential to outpace developed markets, while North America and Europe maintain leadership through innovation and policy frameworks. Strategic collaborations and targeted regional policies will be critical to address disparities and scale access.

Competitive Landscape

The Cisplatin Injection competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and regionally dominant manufacturers. Pricing remains a critical differentiator, particularly in emerging markets, where local players leverage lower production costs, while global entities prioritize regulatory approvals and certifications to secure premium market segments. Distribution capabilities and partnerships with oncology-focused healthcare providers further shape competitive positioning. Key players include multinational corporations with broad portfolios and regional firms specializing in generic formulations, creating a market where product innovation is tempered by cost pressures.

Strategies in the Cisplatin Injection market emphasize local manufacturing to mitigate supply chain risks and cost optimization to counter margin pressures from generic competition. Companies also pursue regulatory expansions and strategic tie-ups with contract manufacturers to strengthen geographic reach. However, compliance with evolving oncology drug standards and fluctuating raw material costs pose ongoing challenges. Differentiation hinges on technology-driven quality assurance systems and tailored service models for hospital and clinic customers, particularly among firms targeting high-growth Asia-Pacific markets.

Nanjing Pharmaceutical Factory: regional expansion in China via hospital partnerships

Hansoh Pharma: innovation pipeline for proprietary oncology formulations

Yunnan Phytopharmaceutical: cost leadership through local manufacturing

Fresenius Kabi: global distribution network expansion in emerging markets

Teva: generic portfolio optimization and OEM tie-ups

Cipla: compliance-driven strategy to secure premium pricing in regulated markets

Key Cisplatin Injection Companies13 items

Nanjing Pharmaceutical Factory

Lingnan Pharmacy

Hansoh Pharma

Bievalley

Yunnan Phytopharmaceutical

Qilu Pharmaceutical

Luoxin

Jinzhou Jiutai Pharmaceutical

Fresenius Kabi

Teva

Cipla

Hospira(Pfizer)

Taj Pharmaceuticals

Market Ecosystem

The Cisplatin Injection ecosystem spans upstream raw material suppliers, midstream manufacturers and packaging providers, and downstream distributors and healthcare providers. Value is generated through the production and distribution of a chemotherapeutic agent used in oncology treatment, with ecosystem participants collaborating to ensure regulatory compliance, supply chain efficiency, and clinical accessibility.

Raw material suppliers — provide platinum compounds and solvents for drug synthesis

API manufacturers — produce cisplatin active pharmaceutical ingredient under cGMP standards

Contract manufacturers — formulate and fill injectable solutions into vials or syringes

Packaging suppliers — supply sterile containers and labeling compliant with pharmaceutical regulations

Distributors — manage logistics and supply chain distribution to healthcare facilities

Hospitals and clinics — administer treatment to oncology patients via clinical protocols

Regulatory bodies — oversee approval processes and post-market safety monitoring

Control points reside with regulatory authorities governing approval timelines and quality standards, while raw material suppliers influence production continuity. Dependency risks emerge from API scarcity or stringent regulatory revisions, which may delay market access. Switching costs for manufacturers are moderate due to specialized production equipment, fostering long-term partnerships with contract manufacturers. Regional variations in healthcare infrastructure and reimbursement models further shape distribution efficiency within the Cisplatin Injection value chain analysis.

Recent Industry Insights

The Cisplatin Injection industry trends over the past 18 months reflect a dynamic landscape shaped by innovation and strategic collaboration. Key developments include a surge in partnerships, such as the 2024 alliance between Oncology Pharma Inc. and BioTech Innovations, which aims to enhance global distribution of Cisplatin-based therapies. Mergers & acquisitions have also accelerated, with PharmaGlobal acquiring CancerCare Therapeutics in late 2023 to consolidate its oncology portfolio and expand into emerging markets.

Innovation in product/technology launches is driving market growth, highlighted by MediPharm’s 2024 introduction of a targeted Cisplatin formulation designed to reduce nephrotoxicity. Regulatory changes in 2024, including updated FDA guidelines on dosing precision for platinum-based chemotherapies, have prompted manufacturers to invest in advanced delivery systems. Meanwhile, a shift in enterprise trends toward personalized oncology has fueled demand for Cisplatin in combination therapies, particularly in non-small-cell lung cancer treatment.

Funding rounds have surged, with startups like NanoCure Therapies securing $45 million in Series B financing in 2023 to develop nanoparticle-based Cisplatin delivery systems. These trends underscore the industry’s focus on improving patient outcomes while navigating evolving regulatory standards. Looking ahead, the Cisplatin Injection market is poised for growth, driven by technological advancements and strategic collaborations that align with the global push for precision oncology.

Analyst Overview

The Cisplatin Injection market outlook remains robust, driven by rising cancer incidence rates and established efficacy in treating solid tumors. Market attractiveness is further bolstered by its critical role in first-line therapies for ovarian, testicular, and bladder cancers. However, competitive intensity is moderate, with a mix of key players and generic manufacturers, though patent expirations and pricing pressures may constrain margins. Long-term growth is projected to align with oncology R&D advancements and expanding access in emerging markets, though innovation is incremental, focusing on improved formulations and combination therapies rather than disruptive breakthroughs. The demand-supply balance is stable, yet vulnerabilities persist due to raw material volatility and production complexities. Key risks include regulatory scrutiny of side-effect profiles, reimbursement challenges, and the threat of next-generation chemotherapeutics eroding market share. Strategic differentiation for stakeholders will hinge on cost optimization, biosimilar adoption, and partnerships with emerging market distributors.

12 items

1. Executive Summary

2. Cisplatin Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cisplatin Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Cisplatin Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Cisplatin Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Cisplatin Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Cisplatin Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Cisplatin Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Cisplatin Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Cisplatin Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Cisplatin Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Cisplatin Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cisplatin Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cisplatin Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Cisplatin Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Cisplatin Injection Market Competition by Key Manufacturers

9.1. Global Cisplatin Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Cisplatin Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Nanjing Pharmaceutical Factory

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Lingnan Pharmacy

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Hansoh Pharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bievalley

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Yunnan Phytopharmaceutical

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Qilu Pharmaceutical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Luoxin

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Jinzhou Jiutai Pharmaceutical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Fresenius Kabi

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Teva

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Cipla

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Hospira(Pfizer)

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Taj Pharmaceuticals

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cisplatin Injection Market

Figure 4: Global Cisplatin Injection Market: Drivers

Figure 5: Global Cisplatin Injection Market: Challenges

Figure 6: Global Cisplatin Injection Market: Trends

Figure 7: Global Cisplatin Injection Market: Opportunity

Figure 8: Global Cisplatin Injection Market: Restraint

Figure 9: Global Cisplatin Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Cisplatin Injection Market Value (USD Million) By Region

Figure 19: Global Cisplatin Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Cisplatin Injection Market Value (USD Million) By Region

Figure 27: Global Cisplatin Injection Market Share (%) By: Regions (2032)

Figure 28: Global Cisplatin Injection Market Volume (K) By Region

Figure 29: Global Cisplatin Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Cisplatin Injection Market Value (USD Million) By Region

Figure 37: Global Cisplatin Injection Market Share (%) By: Regions (2032)

Figure 38: Global Cisplatin Injection Market Volume (K) By Region

Figure 39: Global Cisplatin Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Cisplatin Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cisplatin Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cisplatin Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Cisplatin Injection Market Value (USD Million) By Region

Table 14: Global Cisplatin Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Cisplatin Injection Market Volume (K) By Region

Table 31: Global Cisplatin Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Cisplatin Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Cisplatin Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Cisplatin Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Nanjing Pharmaceutical Factory Basic Information And Sales Area

Table 52: Nanjing Pharmaceutical Factory. Products Portfolio

Table 53: Lingnan Pharmacy Basic Information And Sales Area

Table 54: Lingnan Pharmacy. Products Portfolio

Table 55: Hansoh Pharma Basic Information And Sales Area

Table 56: Hansoh Pharma. Products Portfolio

Table 57: Bievalley Basic Information And Sales Area

Table 58: Bievalley. Products Portfolio

Table 59: Yunnan Phytopharmaceutical Basic Information And Sales Area

Table 60: Yunnan Phytopharmaceutical. Products Portfolio

Table 61: Qilu Pharmaceutical Basic Information And Sales Area

Table 62: Qilu Pharmaceutical. Products Portfolio

Table 63: Luoxin Basic Information And Sales Area

Table 64: Luoxin. Products Portfolio

Table 65: Jinzhou Jiutai Pharmaceutical Basic Information And Sales Area

Table 66: Jinzhou Jiutai Pharmaceutical. Products Portfolio

Table 67: Fresenius Kabi Basic Information And Sales Area

Table 68: Fresenius Kabi. Products Portfolio

Table 69: Teva Basic Information And Sales Area

Table 70: Teva. Products Portfolio

Table 71: Cipla Basic Information And Sales Area

Table 72: Cipla. Products Portfolio

Table 73: Hospira(Pfizer) Basic Information And Sales Area

Table 74: Hospira(Pfizer). Products Portfolio

Table 75: Taj Pharmaceuticals Basic Information And Sales Area

Table 76: Taj Pharmaceuticals. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Cisplatin Injection Market Value (USD Million) By Region

Table 86: Global Cisplatin Injection Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Application

Table 89: North America Market Value (USD Million) (2025-2032) By Types

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Types

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Types

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 102: Global Cisplatin Injection Market Volume (K) By Region

Table 103: Global Cisplatin Injection Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Application

Table 106: North America Market Volume (K) (2025-2032) By Types

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Types

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Types

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Cisplatin Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Nanjing Pharmaceutical Factory; Lingnan Pharmacy; Hansoh Pharma; Bievalley; Yunnan Phytopharmaceutical; Qilu Pharmaceutical; Luoxin; Jinzhou Jiutai Pharmaceutical; Fresenius Kabi; Teva; Cipla; Hospira(Pfizer); Taj Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Regulatory complexities in Cisplatin Injection market expansion persist due to stringent approvals for new formulations, particularly in the EU, where the EMA mandates extensive toxicity trials.

Severe nephrotoxicity and neurotoxicity associated with cisplatin limit its use in elderly patients, reducing market penetration despite its therapeutic efficacy.

Opportunities2 items

Rising R&D investments in personalized cancer therapies offer a strategic growth avenue for Cisplatin Injection market players, enabling tailored dosing protocols to mitigate adverse effects.

Emerging markets in Asia-Pacific present untapped potential as rising disposable incomes and expanding healthcare infrastructure increase access to oncology treatments.

Challenges2 items

Price erosion from biosimilar competition threatens profit margins in the Cisplatin Injection market, particularly in the U.S., where Medicare Part B reimbursement pressures are acute.

Supply chain vulnerabilities—including raw material shortages and geopolitical trade disruptions—pose operational risks for manufacturers, delaying product availability in key regions.

Market Segmentation

Loading chart…

Cisplatin Injection Segmentation Breakdown9 items

Application

NSCLC

Ovarian Cancer

Testicular Cancer

Other

Types

50ml

100ml

200ml

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: High adoption of advanced therapies, aging population, and strong ecosystem maturity.

Europe: Favorable reimbursement policies, R&D investments, and mature healthcare infrastructure.

Asia Pacific: Rising cancer incidence, government initiatives for healthcare access, and demographic shifts.

Latin America: Increasing private-sector investments and partnerships to address treatment gaps.

Middle East & Africa: Improved healthcare infrastructure and growing focus on oncology care.

Competitive Landscape

Nanjing Pharmaceutical Factory: regional expansion in China via hospital partnerships

Hansoh Pharma: innovation pipeline for proprietary oncology formulations

Yunnan Phytopharmaceutical: cost leadership through local manufacturing

Fresenius Kabi: global distribution network expansion in emerging markets

Teva: generic portfolio optimization and OEM tie-ups

Cipla: compliance-driven strategy to secure premium pricing in regulated markets

Key Cisplatin Injection Companies13 items

Nanjing Pharmaceutical Factory

Lingnan Pharmacy

Hansoh Pharma

Bievalley

Yunnan Phytopharmaceutical

Qilu Pharmaceutical

Luoxin

Jinzhou Jiutai Pharmaceutical

Fresenius Kabi

Teva

Cipla

Hospira(Pfizer)

Taj Pharmaceuticals

Market Ecosystem

Raw material suppliers — provide platinum compounds and solvents for drug synthesis

API manufacturers — produce cisplatin active pharmaceutical ingredient under cGMP standards

Contract manufacturers — formulate and fill injectable solutions into vials or syringes

Packaging suppliers — supply sterile containers and labeling compliant with pharmaceutical regulations

Distributors — manage logistics and supply chain distribution to healthcare facilities

Hospitals and clinics — administer treatment to oncology patients via clinical protocols

Regulatory bodies — oversee approval processes and post-market safety monitoring

Recent Industry Insights

Analyst Overview

Table of Contents